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Background: Microalbuminuria is a marker of cardiovascular events. This study investigated the prevalence of
microalbuminuria in the general population and the factors that can affect urinary excretion of albumin.
Methods: Apparently healthy subjects who participated in a health checkup at our hospital were enrolled in this
study (n = 7963, male 64.0%, 56.2 ± 11.8 years old) Urine samples were collected for the measurement of
albumin concentrations, which were expressed as the ratio of urinary albumin to creatinine concentrations
(UACR [mg/g Cr]). Individual salt intake was assessed by estimating the 24-hour urinary salt excretion of subjects.
Results: The mean blood pressure was 124 ± 15/76 ± 10 mmHg and 31.6%, 7.4%, and 44.1% of subjects had
hypertension, diabetes mellitus, and dyslipidemia, respectively. Urinary albumin was detected in 7265 subjects
(91.2%: UACR ≥ 300 mg/g Cr, 0.5%; 300 > UACR ≥ 30 mg/g Cr, 4.6%; 30 > UACR ≥ 20 mg/g Cr, 2.4%; 20 >
UACR ≥ 10 mg/g Cr, 8.7%; 10 > UACR ≥ 5 mg/g Cr, 21.8%; UACR < 5 mg/g Cr, 53.2%). In subjects with detectable
albuminuria, UACR was independently correlated with age, systolic blood pressure, serum creatinine, fasting plasma
glucose, and salt intake after adjustment for possible factors (P < 0.0001).
Conclusion: The prevalence of microalbuminuria was found to be 4.6% in the general population. The urinary
excretion of albumin was closely associated with blood pressure and salt intake. These data indicated the
importance of salt restriction for the prevention of cardiovascular disease and end-stage renal disease.
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Recent studies have established that microalbuminuria is
an important cardiovascular risk factor [1,2]. Clinical
data have demonstrated that left ventricular hyper-
trophy, increased intima-media thickness of the carotid
artery, and subclinical cardiovascular diseases are associ-
ated with microalbuminuria among individuals at high
risk for cardiovascular disease [3-5]. Furthermore, epi-
demiological and experimental studies have established
that high levels of urinary albumin excretion are associ-
ated with an increased incidence of cardiovascular mor-
tality as well as mortality from all causes [6]. Most of
these data came from observations involving high-risk* Correspondence: ydohi@med.nagoya-cu.ac.jp
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reproduction in any medium, provided the orpatients. The association between urinary albumin levels
and increased cardiovascular mortality in high-risk pa-
tients is evident even at urinary albumin levels below the
clinically defined threshold for microalbuminuria.
Urinary albumin excretion is also a predictor of mor-
tality from all causes in the general population [7]. The
excess risk is more attributable to death from cardiovas-
cular causes and this relationship is already apparent at
‘normal’ levels of albuminuria [3,8]. The establishment
of an association between urinary excretion of albumin
and cardiovascular morbidity and mortality in the gen-
eral population may support the measurement of urinary
albumin as a cardiovascular disease marker. This would
enable the identification of individuals who may benefit
from aggressive risk reduction for the primary preven-
tion of cardiovascular disease. Thus, the present study
investigated the range of urinary excretion levels forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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these data we sought to identify factors that may affect
urinary excretion of albumin in the general population.
Methods
The study was performed in accordance with the princi-
ples of the Declaration of Helsinki, and the Ethics Com-
mittee of Enshu Hospital approved the study protocol.
Written informed consent was obtained from all subjects
prior to the start of the study.
Study settings and subjects
A total of 8155 persons who visited our hospital for a
yearly physical checkup from April 2010 to March 2011
were screened for eligibility to be included in the present
study. Subjects with incomplete data were excluded and
the rest of the 7963 subjects were finally included in the
present study. In addition to the routine examination of
subjects in our health checkup program (physical exa-
mination, chest X-ray, electrocardiogram [ECG], and la-
boratory assessment of cardiovascular risk factors), urine
was sampled for the measurement of urinary albumin in
the morning after an overnight fast. Cross-sectional ana-
lyses were performed in order to investigate the preva-
lence of albuminuria and factors closely related to the
urinary excretion of albumin.
Urinary albumin concentrations were measured by a
turbidimetric immunoassay (analytical range ≥ 1.1 mg/L)
and are expressed as the ratio of concentrations of urinary
albumin to urinary creatinine (UACR [mg/g Cr]). UACR
was recorded as 0 mg/g Cr in those subjects with a urinary
albumin concentration below the analytical limit. Micro-
albuminuria was defined according to the recommenda-
tion of the American Diabetes Association and the
National Kidney Foundation (300 > UACR ≥ 30 mg/g Cr)
[9,10]. Individual salt intake was assessed by estimating
the 24-hour urinary salt excretion of subjects and it was
calculated using a previously reported formula [11].
Blood pressure was measured by a standard sphygmo-
manometer, after subjects were seated in a chair for 5 min
with their backs supported as well as their arms supported
at heart level. Proper cuff size was determined based on
arm circumference. Three consecutive blood pressure
measurements were taken, with two minutes between
each measurement, and the mean of the second and third
measurements was recorded as the blood pressure. Hyper-
tension was defined as systolic blood pressure (SBP) ≥140
mmHg and/or diastolic blood pressure (DBP) ≥ 90
mmHg, or the use of antihypertensive medications. In this
study, diabetes mellitus was defined as fasting plasma glu-
cose ≥ 126 mg/dL or the use of anti-diabetic medications
and dyslipidemia was defined as low-density lipoprotein-
cholesterol (LDL-cholesterol) ≥140 mg/dL, high-density
lipoprotein-cholesterol (HDL-cholesterol) < 40 mg/dL,triglyceride ≥ 150 mg/dL, or the use of antidyslipidemic
medications [12]. ECGs were recorded after subjects
had rested for 1 min in the supine position in an air-
conditioned room.
Statistical analysis
All statistical analyses were performed using StatView
5.0 (SAS Institute, Inc., Cary, USA). Data in the text and
the tables were expressed as mean ± standard deviation.
Because the distribution of UACR was skewed rightward,
these values were expressed as median ± absolute devi-
ation and were log-transformed before statistical ana-
lysis. Differences between two groups were compared by
unpaired Student’s t tests. A corrected chi-square test was
used for comparisons between categorical data. Subjects
were divided into six groups (Figure 1) according to their
urinary level of albumin. The relationship between urinary
excretion of albumin and blood pressure, fasting plasma
glucose, or salt intake was investigated (ANOVA followed
by Scheffe’s post-hoc analysis). Univariate and multivariate
regression analyses were performed in order to investigate
the relationship between urinary levels of albumin and
other variables. A P value of less than 0.05 was considered
to be statistically significant.
Results
The characteristics of all study subjects are shown in
Table 1, with 31.6% having hypertension, 7.4% having dia-
betes mellitus, and 44.1% having dyslipidemia. Of the sub-
jects with these conditions, 66.3%, 67.9%, and 26.0%,
respectively, were under medical treatment for the dis-
order. A total of 1642 subjects (20.6%) were overweight
(body mass index (BMI) > 25 kg/m2. Urinary albumin was
detected in most subjects (n = 7265, 91.2%). More than
half of the subjects (53.2%), had minimal excretion levels
of albumin (UACR < 5 mg/g Cr) and about 4.6% of sub-
jects showed microalbuminuria (300 > UACR ≥ 30mg/g
Cr) (Figure 1).
Regression analyses were performed in a subgroup of
subjects with detectable urinary albumin (urinary albu-
min ≥ 1.1 mg/L; n = 7265, 91.2%). Using univariate re-
gression analysis, UACR was correlated with age, male
gender, waist circumference, BMI, SBP, serum creatin-
ine, uric acid, fasting plasma glucose, dyslipidemia, salt
intake, ECG voltage, and use of inhibitors of the renin-
angiotensin system (Table 2). Age, male gender, SBP,
serum creatinine, fasting plasma glucose, salt intake,
smoking status, ECG voltage, and use of inhibitors of
the renin-angiotensin system were independent predic-
tors of urinary albumin among the variables that show
close correlation with urinary excretion of albumin after
adjustment for possible factors listed in Table 3. Similar
results were obtained in an analysis where all subjects
(n = 7963) were included in the regression model that
Urinary album in (mg/g Cr)
UACR < 5
5 UACR < 10
10 UACR < 20
20 UACR < 30







Figure 1 Distribution of urinary levels of albumin. Urinary albumin was detected in 7265 subjects (UACR ≥ 300 mg/g Cr, n = 41, 0.5%; 300 >
UACR ≥ 30 mg/g Cr, n = 362, 4.6%; 30 > UACR ≥ 20 mg/g Cr, n =192, 2.4%; 20 > UACR ≥ 10 mg/g Cr, n = 694, 8.7%; 10 > UACR ≥ 5 mg/g Cr,
n = 1737, 21.8%; UACR < 5 mg/g Cr, n = 4239, 53.2%). UACR indicates the ratio of the concentrations of urinary albumin to urinary creatinine.
Tanaka et al. BMC Research Notes 2013, 6:256 Page 3 of 7
http://www.biomedcentral.com/1756-0500/6/256used log transformed (UACR + 0.5) as a dependent vari-
able. Age (coefficient 0.113, P < 0.0001), male gender
(−0.154, P < 0.0001), SBP (0.139, P < 0.0001), serum cre-
atinine (0.125, P < 0.0001), salt intake (0.105, P < 0.0001),
smoking (0.124, P < 0.0001), ECG voltage (0.056, P <
0.0001), and use of inhibitors of the renin-angiotensin sys-
tem (0.038, P < 0.001) independently correlated with
UACR after adjustment for waist circumference, uric acid,
fasting plasma glucose, and dyslipidemia (R2 = 0.111, F =
83.0, P < 0.0001). In line with these observations, SBP,
DBP, fasting plasma glucose, and salt intake were observedTable 1 Characteristics of subjects
Total (n = 7963)
Age (years old) 56.2 ± 11.8
Waist circumference (cm) 83.3 ± 8.7
Body mass index (kg/m2) 22.7 ± 3.2
SBP (mmHg) 124.1 ± 15.1
DBP (mmHg) 76.3 ± 9.5
Serum creatinine (mg/dL) 0.76 ± 0.22
Uric acid (mg/dL) 5.5 ± 1.4
Fasting plasma glucose (mg/dL) 95.8 ± 17.9
LDL-cholesterol (mg/dL) 118.5 ± 26.9
HDL-cholesterol (mg/dL) 58.5 ± 13.8
Triglyceride (mg/dL) 107.8 ± 71.4
Urinary albumin (mg/g Cr) 3.89 ± 2.02
Estimated salt intake (g/day) 10.9 ± 3.4
Current smoking (n [%]) 1692 [21.2%]
ECG voltagea (mV) 2.21 ± 0.93
Values are the mean ± standard deviation or the number of subjects, except for uri
pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-den
aElectrocardiogram voltage (SV1 + RV5).to increase with increasing urinary excretion of albumin in
analyses that included all subjects (Figure 2). These results
were further supported by a multivariate logistic regres-
sion analysis where risks of microalbuminuria were calcu-
lated (Table 4).
Discussion
This study demonstrates that the majority of the Japanese
general population has detectable albuminuria but only
4.6% present with abnormal microalbuminuria. There is a
close association between urinary excretion of albumin,Male (n = 5095) Female (n = 2868)
56.0 ± 11.9 55.6 ± 11.7
84.7 ± 8.3 81.0 ± 8.9
23.2 ± 3.0 21.9 ± 3.3
125.6 ± 14.8 121.6 ± 15.5
77.7 ± 9.4 73.8 ± 9.0
0.84 ± 0.24 0.62 ± 0.10
6.0 ± 1.3 4.5 ± 1.0
98.1 ± 19.5 91.7 ± 13.6
118.5 ± 27.0 118.4 ± 26.7
55.6 ± 13.1 63.8 ± 13.5
119.9 ± 80.7 86.2 ± 43.4
3.84 ± 2.13 3.94 ± 1.81
12.3 ± 3.1 8.3 ± 2.1
1547 [30.4%] 145 [5.1%]
2.33 ± 0.97 2.00 ± 0.82
ne albumin (median ± absolute deviation). SBP indicates systolic blood
sity lipoprotein, Cr; creatinine.
Table 2 Results of univariate analyses demonstrating the
relationship between urinary albumin and other variable
Standardized coefficient P value
Age 0.251 < 0.0001
Gender; male 0.040 < 0.001
Waist circumference 0.120 < 0.0001
Body mass index 0.076 <0.0001
SBP 0.243 < 0.0001
Serum creatinine 0.116 < 0.0001
Uric acid 0.043 < 0.001
Fasting plasma glucose 0.221 < 0.0001
LDL-cholesterol −0.006 0.61
HDL-cholesterol −0.057 < 0.0001
Triglyceride 0.075 < 0.0001
Dyslipidemia 0.077 < 0.0001
Estimated salt intake 0.209 < 0.0001
Current smoking 0.015 0.21
ECG voltagea 0.099 < 0.0001
RAS inhibitors 0.145 < 0.0001
Univariate analysis was conducted in subjects with detectable urinary albumin
(n=7265). SBP indicates systolic blood pressure; LDL, low-density lipoprotein;
HDL, high-density lipoprotein; RAS, renin-angiotensin system.
aElectrocardiogram voltage (SV1 + RV5).
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mortality. This association suggests that an approach of
reducing urinary albumin could be used to prevent cardio-
vascular disease, which is a leading cause of death. Life-
style modification is one possible mechanism to improveTable 3 Multivariate regression analysis demonstrates
the relationship of urinary excretion of albumin to other
variables
R2 = 0.163, F = 117.4, P < 0.0001
Standardized coefficient P value
Age 0.152 < 0.0001
Gender; male −0.215 < 0.0001
Waist circumference −0.017 0.16
SBP 0.130 < 0.0001
Serum creatinine 0.135 < 0.0001
Uric acid −0.004 0.76
Fasting plasma glucose 0.155 < 0.0001
Dyslipidemia 0.006 0.59
Estimated salt intake 0.185 < 0.0001
Current smoking 0.103 < 0.0001
ECG voltagea 0.055 < 0.0001
RAS inhibitors 0.054 < 0.0001
Analysis in subjects with detectable urinary albumin (n = 7265).
SBP indicates systolic blood pressure; RAS, renin-angiotensin system.
aElectrocardiogram voltage (SV1 + RV5).urinary excretion of albumin because both salt intake and
SBP independently correlate with urinary albumin.
Several studies have reported on the prevalence of
microalbuminuria in the general population including 7%
of subjects in the PREVEND study, and 3.8% of subjects in
the INTERMAP study. The prevalence of subjects with
microalbuminuria in those studies are similar to the
present study [13,14]. In contrast, the Takahata study
reported that the prevalence of microalbuminuria was
13.7% in the general population [15]. We observed that
the excretion of urinary albumin is closely associated with
age, male gender, blood pressure, salt intake, and various
other factors. Thus, the discrepancy in the prevalence of
microalbuminuria between the present study and previous
studies may be attributable to differences in the character-
istics of the subjects studied. Indeed, the mean age was
older and the blood pressure was higher in the Takahata
study than in the present study. A linear correlation of
urinary excretion of albumin with future cardiovascular
and non-cardiovascular death was observed in the
PREVEND study and the adjusted hazard of major cardio-
vascular events was increased by 5.9% for every 0.4 mg/
mmol increase in UACR levels in the HOPE trial [1,7].
These studies demonstrate that even small increases in
urinary excretion of albumin within the ‘normal level’ can
increase the risk of future cardiovascular events. Further-
more, a reduction in urinary albumin levels is associated
with a reduction in cardiovascular events [16,17]. These
observations suggest that urinary excretion of albumin
may be a surrogate marker that will useful for the evalu-
ation of individual risk in clinical settings. The findings of
others in combination with the findings of this study indi-
cate that many people may benefit from intensive inter-
vention to reduce or normalize the urinary excretion of
albumin.
The beneficial effects of inhibitors of the renin-
angiotensin system on urinary albumin have already
been established [13,18-20]. However, in most cases
medical intervention is not realistic because of the wide
prevalence of albuminuria, including ‘normal’ albumi-
nuria, in the general population. A public health ap-
proach aimed at lifestyle modification that includes
restriction of salt intake and high calorie diet, may be
effective, because of the observed close relationship
between urinary excretion of albumin and salt intake,
SBP, and fasting plasma glucose.
Although the present study does not establish a causal
relationship between the urinary excretion of albumin
with other factors, several mechanisms underlying the
observed relationship can be proposed. The kidney is an
important target organ of hypertension and the relation-
ship between increased blood pressure and albuminuria
has been established. Excess salt intake produces an ex-






























































































Trend P < 0.0001
Trend P < 0.0001Trend P < 0.0001
Figure 2 The relationship of urinary albumin with blood pressure, plasma glucose, and salt intake (n=7963). The solid and hatched
horizontal bars in the upper part of the figure denote that a significant difference was determined by Scheffe’s post-hoc test with P < 0.001 or P < 0.05,
respectively. UACR indicates the ratio of the concentrations of urinary albumin to urinary creatinine.
Tanaka et al. BMC Research Notes 2013, 6:256 Page 5 of 7
http://www.biomedcentral.com/1756-0500/6/256intra-glomerular pressure and glomerular hyperfiltration,
which results in urinary excretion of albumin. An in-
crease in blood pressure is also involved in the mecha-
nism underlying salt-induced albuminuria. An elevated
fasting plasma glucose level indicates the presence ofTable 4 Results of logistic regression analysis
demonstrating a risk of microalbuminuria
Odd’s ratio (95%CI) P value
Age (years) 1.047 (1.035–1.059) < 0.0001
Gender; male 0.467 (0.324–0.671) < 0.0001
Waist circumference (cm) 1.010 (0.996–1.024) 0.16
SBP (mmHg) 1.027 (1.020–1.035) < 0.0001
Serum creatinine (mg/dL) 7.090 (3.863–13.015) < 0.0001
Uric acid (mg/dL) 1.081(0.983–1.188) 0.11
Fasting plasma glucose (mg/dL) 1.019 (1.015–1.023) < 0.0001
Dyslipidemia 1.132 (0.908–1.412) 0.27
Estimated salt intake (g/day) 1.142 (1.103–1.183) < 0.0001
Current smoking 2.040 (1.553–2.681) < 0.0001
ECG voltagea 1.151 (1.030–1.285) < 0.05
RAS inhibitors 1.485 (1.150–1.917) < 0.01
Logistic analysis in all subjects (n = 7963).
SBP indicates systolic blood pressure; RAS, renin-angiotensin system.
aElectrocardiogram voltage (SV1 + RV5).insulin resistance that promotes sodium re-absorption and
may increase the volume load. Alternatively, endothelial
dysfunction may be involved in the mechanism underlying
the observed relationship between urinary excretion of al-
bumin and other factors [21-23]. Many factors that have a
close association with the urinary excretion of albumin in
the present study also promote atherosclerosis. Since
endothelial dysfunction is an early step of atherosclerosis,
these factors may cause urinary albumin excretion via
endothelial damage [24]. Indeed, in the Hoorn study, a
linear association of microalbuminuria with endothelium
function as assessed by flow-mediated vasodilation was
observed in subjects either with or without diabetes
[22]. Furthermore, inhibition of the endothelial nitric oxide
pathway causes albuminuria [23]. The positive correlation
between the use of inhibitors of the renin-angiotensin
system and urinary albumin may have been attributable
to high prevalence of microalbuminuria among hyper-
tensive patients as compared to normotensive subjects.
Alternatively, patients with albuminuria may have been
preferably prescribed with renin-angiotensin system in-
hibitors though the prevalence of microalbuminuria was
not significantly different between hypertensive patients
with and without renin-angiotensin system inhibitors
(data not shown).
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following conditions. Firstly, the urinary excretion of albu-
min was measured only once. Secondly, study subjects were
participants in our health checkup program, which could
introduce a selection bias. Thirdly, clinical significance of
albuminuria as a cardiovascular risk was not assessed in the
present study. Finally, a causal relationship cannot be
established because this was a cross-sectional study. Longi-
tudinal follow-up studies are necessary to draw a definite
conclusion.
Conclusion
The majority of the general population has detectable uri-
nary excretion of albumin and 4.6% show microalbuminuria.
The urinary excretion of albumin was shown to be closely
associated with salt intake as well as blood pressure. These
data indicate the importance of dietary salt restriction for the
prevention of cardiovascular disease as well as end-stage
renal disease.
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